Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efgartigimod effect on Pneumovax 23 vaccine response in healthy adults
NL-OMON50337Active, not recruiting
- Sponsor
- argenx
- Start
- Nov 2021
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Randomised, open-label trial of efgartigimod alfa and 23-valent pneumococcal polysaccharide vaccine in autoimmune disease (3 arms), sponsored by argenx. Started Nov 2021; status: active, not recruiting.
02
Drugs
efgartigimod alfa23-valent pneumococcal polysaccharide vaccine
03
Conditions
autoimmune disease
Beyond the preview
Go deeper on NL-OMON50337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50337.